All News

TMS 2025: Katrina Wugalter, MA, explains why treating vasomotor symptoms may be key to improving cognitive function during menopause.

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

TMS 2025: Donna Plecha, MD, an expert in breast imaging, discusses essential breast cancer screening recommendations for primary care physicians.

TMS: New preliminary data show reduction in bothersome VMS as early as week 4, an effect that led to statistically significant improvements across other life domains.

TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

TMS: Black women are up to 36% less likely to receive a prescription for systemic estrogen than White women, despite more acute and persistent VMS, authors said.

Your daily dose of the clinical news you may have missed.

New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.

TMS 2025: Early natural menopause significantly raises the risk of metabolic syndrome, highlighting the need for proactive health interventions in at-risk women.

Plasma assays combining p-tau217 and Aβ42/40 accurately confirm AD, supporting patient eligibility for anti-amyloid disease-modifying therapies.

Your daily dose of the clinical news you may have missed.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

Tezepelumab's approval marks the first for a TSLP-targeting biologic for CRSwNP, backed by WAYPOINT trial data showing sustained symptom and polyp reduction.

GRAIL's PATHFINDER 2 study shows Galleri blood test detected 7 times more cancers when added to standard screenings, with 99.6% specificity and low false positives.

Your daily dose of the clinical news you may have missed.